Gamida Cell Ltd.’s $35 Million Follow-On Offering

Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd.

The ordinary shares are listed on the Nasdaq Global Market under the symbol “GMDA.”

Based in Jerusalem, Israel, Gamida Cell is a clinical stage biopharmaceutical company that leverages its proprietary nicotinamide-, or NAM-, based cell expansion technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases.

RBC Capital Markets, JMP Securities, Oppenheimer & Co. and Needham & Company acted as underwriters on the deal.

The Davis Polk corporate team included partner Derek Dostal (Picture) and associates Sana Bargach and Ariel Rivera. The tax team included partner Rachel D. Kleinberg and associate Tomislava Dragicevic. The intellectual property and technology team included partner David R. Bauer and associate Jesse L. Hallock. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Sana Bargach – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Derek Dostal – Davis Polk & Wardwell; Tomislava Dragicevic – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Ariel Rivera – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: JMP Securities LLC; Needham & Company; Oppenheimer & Co; RBC Capital Markets;

Author: Ambrogio Visconti